SMART Protocol for Asthma Management
Introduction to SMART Protocol
- The Global Initiative for Asthma and the National Asthma Education and Prevention Program recommend the SMART protocol for steps 3 and 4 of asthma management, which involves using a single inhaler containing both an inhaled corticosteroid and formoterol for daily maintenance therapy and as-needed symptom relief 1
- SMART protocol is primarily studied and approved for patients 12 years and older 2
Inhalers Compatible with SMART Protocol
- Mometasone/formoterol can potentially be used in SMART protocol as it contains formoterol, though less extensively studied than budesonide/formoterol 1, 2
- Formoterol is the key component that enables the SMART approach due to its rapid onset of action similar to short-acting beta-agonists 1, 2
Important Considerations for SMART Protocol
- Not all ICS/LABA combinations can be used for SMART protocol, such as Fluticasone/salmeterol and Fluticasone/vilanterol, because they do not contain formoterol or have a delayed onset of action 1, 2
- Insurance coverage may limit access to multiple inhalers of the same type, creating challenges for implementing SMART protocol 1
- Patient education is crucial, as patients must clearly understand which inhaler to use as both maintenance and reliever 1
- SMART is not currently recommended for step 5 treatment in the NAEPP guidelines due to limited high-quality studies, though GINA guidelines suggest continuing this approach 1
- SMART is an off-label use in some regions despite strong evidence supporting its efficacy 2